Citius Oncology, a subsidiary of Citius Pharmaceuticals, has announced an exclusive distribution agreement with Unipha. This strategic partnership aims to make Lymphir (denileukin diftitox-cxdl), its targeted immune therapy, available across the European Union and other non-U.S. markets. The agreement marks Citius Oncology's third international distribution collaboration, significantly expanding the global reach for its treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). This move is poised to enhance Citius Pharmaceuticals' market presence and unlock new revenue streams. The expansion into the EU represents a key step in globalizing access to this critical therapy.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis